| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259897 |
|
|
Homo sapiens |
Chronic Lymphocytic Leukemia Cell |
| pmid |
sentence |
| 28580841 |
Ofatumumab is a human IgG1κ monoclonal antibody that binds to a membrane-proximal epitope of CD20 molecule expressed on the surface of B lymphocytes. Ofatumumab, the second-generation anti-CD20 antibody, induces cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity. Ofatumumab is approved as monotherapy and in combination with chlorambucil for the treatment of fludarabine- and alemtuzumab-refractory CLL patients and previously untreated CLL patients, respectively. |
|
4.0
ofatumumab
binding